Table 4.
Relationship between disease-free survival with clinico-pathological factors
|
Variable N = 112 |
1-year DFS (months ± SD) |
2-year DFS (months ± SD) |
5-year DFS (months ± SD) |
Univariate analysis p |
Multivariate analysis HR (95% CI) p |
| Age (years) | 0.09 | ||||
| >50 | 92 ± 3 | 82 ± 5 | 82 ± 5 | ||
| <50 | 96 ± 2 | 94 ± 2 | 92 ± 3 | ||
| Clinical T stage* | 0.05 | ||||
| T2 | 90 ± 6 | 86 ± 7 | 86 ± 7 | ||
| T3 | 98 ± 2 | 96 ± 2 | 96 ± 2 | ||
| T4 | 87 ± 5 | 82 ± 6 | 78 ± 6 | ||
| Clinical N stage* | 0.79 | ||||
| N1 | 92 ± 3 | 90 ± 4 | 90 ± 4 | ||
| N2/N3 | 92 ± 3 | 87 ± 4 | 84 ± 5 | ||
| Clinical stage* | 0.03 | 3.1 (1.02–9.74,) 0.0406 | |||
| IIB/IIIA | 95 ± 2 | 93 ± 3 | 93 ± 3 | ||
| IIIB | 87 ± 5 | 82 ± 6 | 78 ± 6 | ||
| Estrogen receptors | 0.012 | 0.3 (0.91–1.22,) 0.97 | |||
| Negative | 92 ± 3 | 85 ± 4 | 83 ± 4 | ||
| Positive | 97 ± 2 | 93 ± 3 | 93 ± 3 | ||
| Histological grade† | 0.04 | 3.5 (0.79–16.28,) 0.98 | |||
| Low/moderate | 100 | 97 ± 2 | 94 ± 3 | ||
| High | 91 ± 3 | 83 ± 4 | 83 ± 4 | ||
| Pathological response | 0.56 | ||||
| pCR/microscopic | 92 ± 3 | 88 ± 3 | 86 ± 4 | ||
| Residual | 94 ± 4 | 91 ± 4 | 91 ± 4 |
Abbreviations: DFS = disease-free survival; SD = standard deviation; HR = Hazard ratio; 95% CI = 95% confidence interval.
* 6th edition of the American Joint Committee on Cancer TNM classification and staging system.
† Scarff-Bloom-Richardson (SBR) scale.